Nucala is the first and only anti-IL-5 add-on treatment approved in Canada that targets eosinophilic inflammation in adults with chronic rhinosinusitis with nasal polyps – GSK

Nucala (mepolizumab) is now approved in Canada as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) inadequately controlled by intranasal corticosteroids alone. This is the fourth approved indication for Nucala for Canadian patients with eosinophilic driven diseases and is the first and only anti-IL-5 add-on treatment that targets eosinophilic inflammation in adults with CRSwNP.

“As the first anti-IL-5 for Canadians living with chronic rhinosinusitis with nasal polyps, this Nucala approval is an important new treatment option, particularly for patients with severe CRSwNP ( chronic rhinosinusitis with nasal polyps) who may have previously relied on oral steroids and recurrent surgery to manage their condition,” said Marni Freeman, Country Medical Director at GSK Canada. “With more than 50 years experience in developing and manufacturing respiratory medicines, we’re proud of this new indication as it represents yet another treatment option to address the unmet medical needs of patients living with eosinophilic driven diseases.”</p.